Emerging evidence has shown that PJA2 was aberrantly expressed across cancers and acts as an oncogene or a tumor suppressor in thyroid cancer (96), glioblastoma (97), and gastric cancer (98, 99). This evidence concerns the gene PJA2 and neoplasm.